Pfizer, Tabuk Pharma to provide high-value medicines to society

RIYADH — In line with the Saudi governments “Vision 2030” outlining plans to achieve a thriving economy and a vibrant society, Pfizer Saudi Limited has recently signed an exclusive commercial agreement with Tabuk Pharmaceuticals (one of the leading pharmaceutical companies in Saudi Arabia and the region in general. The synergistic venture leverages the local manufacturing capabilities of Tabuk and global promotional capabilities of Pfizer Saudi Limited. Under the agreement, Pfizer Saudi Limited will have exclusive rights to promote and distribute branded high-value generics. The unique agreement helps to improve availability of important medicines to the Saudi society in therapeutic areas like central nervous system, kidney dialysis/transplant & urology. Pfizer Innovative Health Cluster Lead of Saudi Arabia Dr. Alaa Gamal said “that Pfizer Saudi Limited is committed to bringing the best in medicines to the Saudi patients and improving access and outcomes for treatment in a cost effective way in above therapeutic areas.” Dr. Hamad Al Khamees, General Manager, Saudi Arabia Tabuk Pharmaceuticals, said “we are excited about this opportunity enabled by the quality of our technical operations. This contributes to further strengthening Saudi Arabia’s local manufacturing industry, and we look forward to more cooperation in the future with Pfizer.” — SG